Update on rifampin drug interactions, III

Archives of Internal Medicine

Volumn 157, Issue 21, 1997, Pages 2453-2458

  Strayhorn, Valerie A ^a   Baciewicz, Anne M ^b   Self, Timothy H ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORAMPHENICOL; CYCLOSPORIN; DAPSONE; DELAVIRDINE; DIAZEPAM; DIGITOXIN; DILTIAZEM; DISOPYRAMIDE; DOXYCYCLINE; FLUCONAZOLE; GLUCOCORTICOID; HALOPERIDOL; ITRACONAZOLE; KETOCONAZOLE; METHADONE; MIDAZOLAM; NIFEDIPINE; NORTRIPTYLINE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; QUINIDINE; RIFAMPICIN; THEOPHYLLINE DERIVATIVE; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL; WARFARIN; ZIDOVUDINE;

DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; DRUG MONITORING; ENZYME INDUCTION; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0030657790     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.21.2453     Document Type: Review

References (54)

1. Baciewicz AM, Self TH. Rifampin drug interactions. Arch Intern Med. 1984;144:1667-1671.
2. Baciewicz AM, Self TH, Bekemeyer WB. Update on rifampin drug interactions. Arch Intern Med. 1987;147:565-568.
3. Borcherding SM, Baciewicz AM, Self TH. Update on rifampin drug interactions II. Arch Intern Med. 1992;152:711-716.
4. Burger DM, Meenhorst PL, Koks CHW, Beijnen JH. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother. 1993;37:1426-1431.
5. Burger DM, Meenhorst PL, ten Napel CH, et al. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions. AIDS. 1994;8:1683-1689.
6. Gallicano K, Sahai J, Foster B, Bouchard J, Cameron DW. Rifampin decreases zidovudine plasma concentrations in HIV-infected patients. Presented at the Fourth Conference on Retroviruses and Opportunistic infections; January 22-26, 1997; Washington, DC.
7. Invirase (saquinavir mesylate) Product Information. Physicians' Desk Reference. 51st ed. Montvale, NJ: Medical Economics Co Inc; 1997:2291-2294.
8. McCrea J, Wyss D, Stone J, et al. Pharmacokinetic interaction between indinavir and rifampin. Clin Pharmacol Ther. 1997;61:152. Abstract.
9. Norvir (ritonavir) Product Information. Physicians' Desk Reference. 51st ed. Montvale, NJ: Medical Economics Co Inc; 1997:447-452.
10. Yuen GJ, Anderson R, Sandoval T, Wu E, Shetty BV, Kerr BM. The pharmacokinetics of nelfinavir administered alone and with rifampin in healthy volunteers. Clin Pharmacol Ther. 1997:61:147. Abstract.
11. Centers for Disease Control and Prevention. Clinical update: impact of HIV protease Inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR Mort Mortal Wkly Rep. 1996;45:921-925.
12. Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther. 1997;61:544-553.
13. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992;14:165-174.
14. Drayton JD, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis. 1994;18:266.
15. Nicolau DP, Crowe HM, Nightingale CH, Quintliani R, Rifampin-fluconazole interaction in critically ill patients. Ann Pharmacother, 1995;29:994-996.
16. Horowitz HW, Jorde UP, Wormser GP. Drug interactions in use of dapsone for Pneumocystis carinii prophylaxis. Lancet. 1992;339:747.
17. Adedoyin A, Kirillova GP, Branch RA. Differential effect of quinidine and rifampin on two oxidative metabolites of dapsone. Clin Pharmacol Ther. 1996;59:136. Abstract.
18. Occhipinti DJ, Choi A, Deyo K, et al. Influence of rifampin and clarithromycin on dapsone disposition and methemoglobin concentrations. Clin Pharmacol Ther. 1995;57:163.
19. Humbert G, Brumpt I, Montay G, et al. Influence of rifampin on the pharmacokinetics of pefloxacin. Clin Pharmacol Ther. 1991;50:682-687.
20. Wallace RJ, Brown BA, Griffith DE, et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M intracellulare Infection. J Infect Dis. 1995;171:747-750.
21. Colmenero JD, Fernandez-Gallardo LC, Agundez JAG, et al. Possible Implications of doxycycline-rifampin interaction for treatment of brucellosis. Antimicrob Agents Chemother. 1994;8:2798-2802.
22. Furlan V, Perello L, Jacquemin E, Debray D, Taburet AM. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. Transplantation. 1995;59:1217-1218.
23. Kiuchi T, Tanaka K, Inomata Y, et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. Transplant Proc. 1996;28:3171-3172.
24. Koselj M, Bren A, Kandus A, Kovac D. Drug Interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections. Transplant Proc. 1994;26:2823-2824.
25. Zylber-Katz E. Multiple drug interactions with cyclosporine in a heart transplant patient. Ann Pharmacother. 1995;29:127-131.
26. Bebchuk JM, Stewart DE. Drug interaction between rifampin and nortriptyline: a case report. Int J Psychiatry Med. 1991;21:183-187.
27. Self TH, Corley CR, Nabhan S, Abell T. Interaction of rifampin and nortriptyline. Am J Med Sci. 1996;311:80-81.
28. Borcherding SM, Bastian TL, Self TH, AbouShala N, LeDuc BW, LaLonde RL. Two-and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism. Antimicrob Agents Chemother.1992;36:1553-1558.
29. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther. 1996;59:7-13.
30. Villikka K, Kivisto KT, Backman JT, Olkkola KT, Neuvonen PJ. Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther. 1997;61:8-14.
31. Holtbecker N, Fromm MF, Droemer HK, Ohnhaus EE, Heidemann H. The nifedipine-rifampin interaction. Drug Metab Dispos. 1996;24:1121-1123.
32. Tada Y, Tsuda Y, Otsuka T, et al. Nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension. Am J Med Sci. 1992;303:25-27.
33. Shin JG, Kim YH, Yoon M, et al. Drug interaction between rifampin and haloperidol concomitantly administered to schizophrenics. Clin Pharmacol Ther. 1996;59:180. Abstract.
34. Surekha V, Peter JV, Jeyaseelan L, Cherian AM. Drug Interaction: rifampicin and glibenclamide. Natl Med J India. 1997;10:11-12.
35. Lee KH, Shin JG, Chong WS, et al. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. Eur J Clin Pharmacol. 1993;45:287-289.
36. Lin FG. Rifampin-induced deterioration in steroid-dependent asthma. J Allergy Clin Immunol. 1996;98:1125.
37. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology. 1996;24:796-801.
38. Villikka K, Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ. Concentrations and effects of zopiclone are greatly reduced by rifampicin. Br J Clin Pharmacol. 1997;43:471-474.
39. Kharasch ED, Russell M, Mautz D, et al. The role of cytochrome P4503A4 in alfentanil clearance. Anesthesiology. 1997;87:36-50.
40. Williamson KM, Patterson JH, Pieper JA, McQueen RH, Adams KF. Effects of erythromycin or rifampin on steady state losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 1997;61:202. Abstract.
41. Li AP, Rasmussen A, Xu L, Kaminski DL. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. J Pharmacol Exp Ther. 1995;274:673-677.
42. Brockmeyer NH, Mertins L, Goos M. Pharmacokinetic interaction of antimicrobial agents and levomethadon in drug-addicted AIDS patients. Klin Wochenschr. 1991;69:16-18.
43. Wenning GK, O'Connell MT, Patsalos PN, Quinn NP. A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculosis therapy in Parkinson's disease. Mov Disord. 1995;10:664-667.
44. Nolan CM, Sandblom RE, Thummel KE, Slattery JT, Nelson SD. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest. 1994;105:408-411.
45. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest. 1991;99:465-471.
46. Dimova S, Stoytchev T. Influence of rifampicin on the toxicity and the analgesic effect of acetaminophen. Eur J Drug Metab Pharmacokinet. 1994;19:311-317.
47. Perez-Gallardo L, Blanco ML, Soria H, Escanero JF. Displacement of rifampicin bound to serum proteins by addition of levamisole. Biomed Pharmacother. 1992;46:173-174.
48. Bhatia RS, Uppal R, Malhi R, Behera D, Jindal SK. Drug interaction between rifampicin and cotrimoxazole in patients with tuberculosis. Hum Exp Toxicol. 1991;10:419-421.
49. Jain A, Mehta VL, Kulshrestha S. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis. Tuber Lung Dis. 1993;74:87-90.
50. Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin infect Dis. 1996;22 (suppl 1):S15-S22.
51. Abedoyin A, Mauro K, Dubisty C, Boyer A, Porter J, Branch RA. Chronic modulation of CYP2D6 and CYP3A4 activities by quinidine and rifampicin respectively. Clin Pharmacol Ther. 1995;58:210. Abstract.
52. Bachmann KA, Jauregui L. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica. 1993;23:307-315.
53. Zhou HH, Feng HJ, Huang SL, Wang W. Inducing effect of rifampin on CYP2C19 is related to gene dose. Clin Pharmacol Ther. 1997:61:227. Abstract.
54. Ged C, Rouillon J, Pichard L, et al. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA Induction. Br J Clin Pharmacol. 1989:28:373-387.